Abeona Therapeutics, Inc. (ABEO)
4.41
-0.02
(-0.45%)
USD |
NASDAQ |
Oct 19, 16:00
4.41
0.00 (0.00%)
After-Hours: 20:00
Abeona Therapeutics Net Income (Quarterly) : -20.19M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.19M |
| March 31, 2026 | -17.08M |
| December 31, 2025 | -20.46M |
| September 30, 2025 | -5.161M |
| June 30, 2025 | 108.83M |
| March 31, 2025 | -12.03M |
| December 31, 2024 | -9.293M |
| September 30, 2024 | -30.27M |
| June 30, 2024 | 7.406M |
| March 31, 2024 | -31.58M |
| December 31, 2023 | -16.59M |
| September 30, 2023 | -11.84M |
| June 30, 2023 | -16.65M |
| March 31, 2023 | -9.107M |
| December 31, 2022 | -1.126M |
| September 30, 2022 | -6.434M |
| June 30, 2022 | -4.097M |
| March 31, 2022 | -22.04M |
| December 31, 2021 | -46.68M |
| September 30, 2021 | -7.044M |
| June 30, 2021 | -15.21M |
| March 31, 2021 | -16.00M |
| December 31, 2020 | -15.83M |
| September 30, 2020 | -7.237M |
| June 30, 2020 | -13.01M |
| Date | Value |
|---|---|
| March 31, 2020 | -48.16M |
| December 31, 2019 | -16.43M |
| September 30, 2019 | -17.37M |
| June 30, 2019 | -23.92M |
| March 31, 2019 | -18.56M |
| September 30, 2018 | -16.42M |
| June 30, 2018 | -12.24M |
| March 31, 2018 | -10.53M |
| December 31, 2017 | -8.45M |
| September 30, 2017 | -5.343M |
| June 30, 2017 | -8.279M |
| March 31, 2017 | -5.247M |
| December 31, 2016 | -7.002M |
| September 30, 2016 | -2.624M |
| June 30, 2016 | -6.703M |
| March 31, 2016 | -5.544M |
| December 31, 2015 | -2.34M |
| September 30, 2015 | -6.073M |
| June 30, 2015 | -4.113M |
| March 31, 2015 | -2.00M |
| December 31, 2014 | -11.94M |
| September 30, 2014 | -1.469M |
| June 30, 2014 | -12.51M |
| March 31, 2014 | -0.859M |
| December 31, 2013 | -1.075M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Ultragenyx Pharmaceutical, Inc. | -92.00M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 11.38M |
| Total Expenses (Quarterly) | 31.57M |
| EPS Diluted (Quarterly) | -0.3539 |
| Enterprise Value | 126.56M |
| Gross Profit Margin (Quarterly) | 57.45% |
| Profit Margin (Quarterly) | -177.4% |
| Earnings Yield | -25.45% |
| Normalized Earnings Yield | -26.21 |